Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Q2 2017 Earnings Presentation
37 slides from Precigen's earnings presentation, Aug 9, 2017
Slide 1: Second Quarter 2017 Financial Results and Business Update
August 9, 2017 Second Quarter 2017 Financial Results and Business Update Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are bas
Slide 3: Collaborations, Marketable Products & Sectors Update
Collaborations, Marketable Products & Sectors Update Andrew Last, Ph.D. – Chief Operating Officer
Slide 4: Precigen: Biotech 2.0 Platform for Human Health
Precigen: Biotech 2.0 Platform for Human Health Intrexon has assembled the world’s leading technology platform for programming and engineering the most pervasive code on the planet Precigen will utilize platform to build next generation therapeutic products faster and cost effectively Broad pipeline
Slide 5: New Collaborations: Microbial Expression Platforms
New Collaborations: Microbial Expression Platforms June 2017 - Entered into an exclusive collaboration with Johnson Matthey (LSE: JMAT), a global leader in science that enables cleaner air, improved health and more efficient use of natural resources, focused on the development of microbial strains f
Slide 6: EnviroFlight: BSF Larvae Production Facility in US
EnviroFlight: BSF Larvae Production Facility in US EnviroFlight - a Joint Venture between Intrexon & Darling Ingredients (NYSE:DAR) Construction of largest commercial-scale black soldier fly (BSF) larvae production facility in US began in May 2017 Significantly expand production of advanced ingredie
Slide 7: AquAdvantage Salmon
AquAdvantage® Salmon AquAdvantage® Salmon First engineered food animal approved by US FDA/Health Canada AquaBounty entered into an agreement to purchase certain assets of Bell Fish Company Land-based farming facility in Albany, Indiana Expected annual capacity of 1200 metric tons à >$10 million a ye
Slide 8: Commercial Launch in Fall 2017
Commercial Launch in Fall 2017 Commercial launch of fresh sliced Arctic® apples in US in Fall of 2017 Non-chemical, preservative-free approach to non-browning No change to apple taste/texture Fresh sliced apple market in US estimated at ~$500 million in sales
Slide 9: Arctic Non-browning Platform
Arctic® Non-browning Platform Arctic® Apple First USDA approved non-browning apple without use of chemical or antioxidant treatments Planting progress and outlook: Anticipate planting over 250,000 Arctic® apple trees during 2017 and over 500,000 in 2018 Planning for 4 million Arctic® apple trees to
Slide 10: Broad Application of Innovative Arctic Solution
Broad Application of Innovative Arctic® Solution Unique Arctic Advantage™ solution creates benefits for commercial tree fruit varieties across the entire supply chain, from growers to consumers Convenience drives consumer purchase selection, especially in healthy snack market Positively impact food
Slide 11: Friendly Aedes
Friendly™ Aedes Friendly™ Aedes Scalable enviro-friendly mosquito solution to suppress the disease-carrying Aedes aegypti Received positive evaluation for European Standard in relation to human health and the environment The National Institute of Public Health and the Environment, Netherlands (RIVM)
Slide 12: Durable Suppression with Oxitec's Solution
Durable Suppression with Oxitec’s Solution Over 80% suppression of Aedes aegypti in CECAP/Eldorado Piracicaba, Brazil maintained in second year with release of nearly 60% less Oxitec mosquitoes as compared to year one Level of control illustrative of strength and durability of Oxitec’s solution Favo
Slide 13: Intrexon Methane Bioconversion Platform
Intrexon Methane Bioconversion Platform Intrexon has developed disruptive MBP technology that enables the profitable use of low cost natural gas to replace oil as the feedstock for several high value industrial products. Need for cleaner burning fuels in automotive and other industries Gas-to-liquid
Slide 14: Significant Gas-to-Liquids Opportunity through MBP
Significant Gas-to-Liquids Opportunity through MBP Intrexon’s Engineered Methanotrophs Chemicals achieved: 2,3 Butanediol* Isobutyraldehyde* 1,4 Butanediol* Isoprene Natural Gas Feedstock Fuels achieved: Isobutanol* Farnesene MBP platform has achieved six different molecules to date. The four molecu
Slide 15: 2,3 Butanediol (BDO) Progress Update
2,3 Butanediol (BDO) Progress Update 2,3 butanediol Methane bioconversion Catalytic conversion Natural gas Butadiene Observed 30% increase in 2,3 BDO yields on top of 30% increase achieved during the first quarter 2,3 BDO test production runs completed in pilot plant Providing 2,3 BDO produced to ch
Slide 16: Harvest Intrexon Enterprise Fund
Harvest Intrexon Enterprise Fund → AD Skincare, Inc. Advanced topical delivery system to improve skin elasticity, firmness and reduction of fine lines and wrinkles → CRS Bio, Inc. Targeted delivery of antibodies for treatment of chronic rhinosinusitis → Exotech Bio, Inc. Innovative exosome platform
Slide 17: Thrive Agrobiotics: Nutrition for Weanling Pigs
Thrive Agrobiotics: Nutrition for Weanling Pigs The Problem: By 2050 global consumption of animal protein will be two-thirds higher than current levels The Opportunity: Pork is the most widely eaten meat in the world today accounting for 36% of global meat consumption Worldwide production of indigen
Slide 18: Leveraging ActoBiotics to Improve Feed Efficiency
Leveraging ActoBiotics® to Improve Feed Efficiency Goal: To develop an advanced feed additive for improved gut health and piglet weaning outcomes Approach: Utilize ActoBiotics® platform to express nutritive proteins targeted for the gastrointestinal tract 2017 Milestones: Positive data from an in vi
Slide 19: Health Sector
Health Sector Andrew Last, Ph.D. – Chief Operating Officer
Slide 20: Clinical Development Outlook for 2017
Clinical Development Outlook for 2017 Patient population # based on United States only; * Estimated new cases per year; **ZIOPHARM plans to initiate pivotal trial in 2017 Indication Gene/Cell Therapy Patient # Phase XON Cost XON Economics Recurrent Glioblastoma Ad-RTS-IL12 >10,000* Phase 3** 0 20% O
Slide 21: Utilizing Sleeping Beauty System in T-Cell Therapies
Utilizing Sleeping Beauty System in T-Cell Therapies Targeting Neoantigens in Solid Tumors With TCR-Modified T Cells Using Non-Viral Sleeping Beauty System CARs: Intrexon, ZIOPHARM, & Merck KGaA Distinctive method centers on proprietary RTS® platform to regulate expression of membrane-bound interleu
Slide 22: Q2 Progress in Oncology Gene & Cell Therapies
Q2 Progress in Oncology Gene & Cell Therapies Pontine Glioma Pre-clinical Study Anti-PD-1 Combination Pre-clinical Study ZIOPHARM Phase 1 study for recurrent glioblastoma (rGBM) Update at ASCO reported median overall survival of 12.5 months, with mean follow-up of 9.2 months (20 mg cohort, N=15) Com
Slide 23: Rare Diseases
Rare Diseases FCX-007 Rare Skin Disease Gene Therapy (Fibrocell Science): Data Safety Monitoring Board recommended continuation of Phase 1/2 clinical trial for treatment of recessive epidermolysis bullosa (RDEB) following planned review of safety data from first adult patient dosed Completed dosing
Slide 24: Completion of GenVec Acquisition
Completion of GenVec Acquisition → Developing a next generation viral platform with significantly higher payload capacity (exceeding 30kb) compared to current viral delivery methods (4.5kb – 9kb) → Will further advance the field of gene-based medicine by enabling delivery of multiple therapeutic eff
Slide 25: Precigen
Precigen Helen Sabzevari, Ph.D. - SVP, Human Therapeutics and Head of R&D for Precigen
Slide 26: Evolution of Precigen: New Model for Bio Pharma
Evolution of Precigen: New Model for Bio Pharma Unique position among Pharma and Biotech Comprehensive suite of technology platforms, through invention and acquisition, under one roof Creation of unique internal portfolio for R&D in various therapeutic areas based on combinations of platforms includ
Slide 27: CAR-T Therapy: Early Promise and Challenges
CAR-T Therapy: Early Promise and Challenges Cutting edge of cancer immunotherapy First FDA approval expected in 2017 for hematological malignancy CAR-T cells expand in patients upon engagement with antigen expressing tumor/normal cells Major challenge of current approaches is significant toxicity du
Slide 28: Regulating CAR-T Cells: RheoSwitch and Kill Switch
Regulating CAR-T Cells: RheoSwitch® and Kill Switch Transgene expression can be turned ON and OFF in dose dependent manner Intrexon’s platform enabling control over efficacy and safety of CAR-T cells RTS® controlled co-expression of cytokines RTS® controlled expression of CAR Kill Switch for selecti
Slide 29: Kill Switch Gene Switch Control of CAR Expression
Kill Switch Gene Switch Control of CAR Expression RheoSwitch® Veledimex ON Veledimex OFF CAR 8 CAR 8 CAR CAR
Slide 30: Improved Persistence with RTS Controlled mbIL-15
Improved Persistence with RTS® Controlled mbIL-15 Veledimex OFF Fold Change in mbIL-15 mRNA over CAR only control CAR 8 7 CAR mbIL-15 CAR Veledimex ON Veledimex dose dependent expression of mbIL-15 can be turned ON and OFF Improved persistence of CAR-T cells by co-expression of mbIL-15 only in prese
Slide 31: Tregs Play A Major Role In Autoimmune Diseases
Tregs Play A Major Role In Autoimmune Diseases Inflammatory bowl Disease (IBD) T1 diabetes (T1D) Multiple Sclerosis (MS) Lupus (SLE) Rheumatoid Arthritis (RA) Regulatory T Cells (Tregs) are critical for control of immune system Tregs have impaired functionality in autoimmune diseases where patient’s
Slide 32: Intrexon's eTregs: Change of Paradigm
Intrexon’s eTregs: Change of Paradigm T cell suppression [%] Overcoming limitations of naturally derived Tregs In vitro studies demonstrate potent suppression of proliferation of effector T cells through engineered Tregs (eTregs) Potential for new wave of therapeutics for various autoimmune diseases
Slide 33: Financial Overview
Financial Overview Joel Liffmann – Senior Vice President, Finance
Slide 34: Second Quarter Financial Performance
Second Quarter Financial Performance * Non-GAAP financial measure. Select Financial Highlights 2Q 2017 2Q 2016 Revenues $54.4 M $52.5 M Collaboration and Licensing Revenues $28.2 M $27.5 M Product & Services and Other Revenues $26.2 M $25.0 M Adjusted EBITDA $(2.0) M* $(5.4)* Impact of change in def
Slide 35: Portfolio Expansion & Maturation
Portfolio Expansion & Maturation June 2017 1 Over 30 January 2011 Collaborations June 2017 $17.5MM $392 Million January 2011 TAF and Received Milestones June 2017 $0 $233 Million January 2011 Cost Recovery Portfolio of Backend Economics Future Milestones & Royalties
Slide 36: Summary
Summary Over 30 collaborations in place capitalizing on our leadership position in the engineering of biology Strong cash position with $157 million in cash, cash equivalents, and short-term investments, and equity securities and preferred stock valued at $168 million Developing high value bio-solut
Slide 37: Q&A Session
INTREXON’ Q&A Session